American Cutaneous Leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.

American Cutaneous Leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate. Br J Dermatol. 2020 Feb 20;: Authors: Senchyna A, Simon S, Cissé H, Ginouves M, Prevot G, Alcoba G, Demar M, Couppie P, Blaizot R Abstract New World cutaneous leishmaniasis (CL) is endemic in many countries of Latin America, including French Guiana 1 . While pentamidine is the first-line treatment against Leishmania guyanensis in this territory 2 , pentavalent antimonials such as meglumine antimoniate (MA) are recommended in case of L. braziliensis or pentamidine-resistant strains of other species 2 . Liposomal amphotericin B (L-AmB) (Ambisome ®) is widely used against fungi and visceral leishmaniasis 3 . However, data concerning its efficacy in New World CL are scarce and contradictory 4-7 . Due to a shortage in MA, the Cayenne Hospital started using L-AmB as an alternative in 2015. We conducted a retrospective study to compare efficacy and safety of L-AmB and MA in patients treated for CL. PMID: 32078162 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research